Purple Biotech Ltd. filed a Form 6-K on August 10, 2026, to furnish its updated corporate presentation dated August 2026. The filing highlights the company's financial position as of June 30, 2026, reporting $6.1 million in cash and a projected runway extending to mid-2027. It outlines the development pipeline for lead candidate IM1240, a tri-specific antibody expected to enter clinical trials in 2027, alongside preclinical data for other programs including CM24 and NT219. The presentation details safety and efficacy results from IND-enabling studies and Phase 2 proof-of-concept data for CM24 in pancreatic cancer. Purple Biotech Ltd. operates in the biotechnology industry, focusing on developing immuno-oncology therapies.

Purple Biotech Ltd. reported second quarter 2026 financial results on August 7, 2026. The company held $6.1 million in cash as of June 30, 2026, providing a runway through mid-2027. R&D expenses rose to $0.7 million from $0.6 million year-over-year, while G&A decreased to $0.6 million from $0.7 million. Operating loss was $1.3 million compared to $1.2 million in the prior period. Net income turned positive at $0.4 million due to a non-cash gain from warrant revaluation, contrasting with a net loss of $1.1 million previously. The company presented new preclinical data for IM1240 at EACR 2026 and plans to enter clinical studies in 2027. Purple Biotech Ltd. is a clinical-stage biotechnology company developing next-generation immunotherapy platforms.